Avalo Therapeutics Statistics Share Statistics Avalo Therapeutics has 13.15M
shares outstanding. The number of shares has increased by 11.62%
in one year.
Shares Outstanding 13.15M Shares Change (YoY) 11.62% Shares Change (QoQ) 1.46% Owned by Institutions (%) 78.51% Shares Floating 10.46M Failed to Deliver (FTD) Shares 3,163 FTD / Avg. Volume 1.69%
Short Selling Information The latest short interest is 90.24K, so 0.69% of the outstanding
shares have been sold short.
Short Interest 90.24K Short % of Shares Out 0.69% Short % of Float 0.69% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -1.72 and the forward
PE ratio is -1.54.
Avalo Therapeutics's PEG ratio is
0.02.
PE Ratio -1.72 Forward PE -1.54 PS Ratio 136.95 Forward PS 122.8 PB Ratio 0.45 P/FCF Ratio -1.23 PEG Ratio 0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Avalo Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 19.96,
with a Debt / Equity ratio of 0.
Current Ratio 19.96 Quick Ratio 19.96 Debt / Equity 0 Debt / EBITDA -0.01 Debt / FCF -0.01 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $19.17K Profits Per Employee $-1.53M Employee Count 23 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 114K Effective Tax Rate -0.33%
Stock Price Statistics The stock price has increased by 3.2% in the
last 52 weeks. The beta is 0.82, so Avalo Therapeutics's
price volatility has been higher than the market average.
Beta 0.82 52-Week Price Change 3.2% 50-Day Moving Average 6.9 200-Day Moving Average 7.08 Relative Strength Index (RSI) 63.41 Average Volume (20 Days) 186,726
Income Statement In the last 12 months, Avalo Therapeutics had revenue of 441K
and earned -35.13M
in profits. Earnings per share was -4.32.
Revenue 441K Gross Profit 807K Operating Income -68.51M Net Income -35.13M EBITDA -68.34M EBIT -68.51M Earnings Per Share (EPS) -4.32
Full Income Statement Balance Sheet The company has 134.55M in cash and 568K in
debt, giving a net cash position of 133.98M.
Cash & Cash Equivalents 134.55M Total Debt 568K Net Cash 133.98M Retained Earnings -370.26M Total Assets 126.58M Working Capital 105.93M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -49.06M
and capital expenditures 0, giving a free cash flow of -49.06M.
Operating Cash Flow -49.06M Capital Expenditures n/a Free Cash Flow -49.06M FCF Per Share -6.04
Full Cash Flow Statement Margins Gross margin is 182.99%, with operating and profit margins of -15535.6% and -7965.76%.
Gross Margin 182.99% Operating Margin -15535.6% Pretax Margin -7939.91% Profit Margin -7965.76% EBITDA Margin -15497.28% EBIT Margin -15535.6% FCF Margin -11123.81%
Dividends & Yields AVTX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for AVTX is $30,
which is 221.2% higher than the current price. The consensus rating is "Buy".
Price Target $30 Price Target Difference 221.2% Analyst Consensus Buy Analyst Count 7
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Dec 29, 2023. It was a
backward
split with a ratio of 1:240.
Last Split Date Dec 29, 2023 Split Type backward Split Ratio 1:240
Scores Altman Z-Score -2.43 Piotroski F-Score 2
